单纯全脑放疗对比贝伐珠单抗、依托泊苷和顺铂诱导后全脑放疗治疗乳腺癌未治脑转移:一项随机临床试验
这项开放标签、随机、多中心临床试验在台湾纳入118例乳腺癌脑转移患者,按2:1随机分配至BEEP诱导3周期后全脑放疗组或单纯全脑放疗组。主要终点脑特异性无进展生存期(PFS)在两组间无显著差异(风险比0.71,95%CI 0.44-1.13,P=0.15;预设α≤0.20),但实验组8个月脑特异性PFS率显著更高(48.7% vs 26.3%,P=0.03)。
要点
- BEEP诱导后全脑放疗对比单纯全脑放疗,中位脑特异性PFS为8.1个月 vs 6.5个月(HR 0.71,95%CI 0.44-1.13,P=0.15)。
- 实验组8个月脑特异性PFS率显著高于对照组(48.7% vs 26.3%,P=0.03)。
- 2个月脑特异性客观缓解率两组无显著差异(BEEP组41.9% vs 全脑放疗组52.6%)。
核心结论
- 全脑放疗前给予BEEP诱导治疗可能改善乳腺癌脑转移的控制,相比直接全脑放疗可能满足对有效全身治疗的需求。
研究设计与样本
- 开放标签、随机、多中心临床试验,2014年9月9日至2018年12月24日在台湾评估乳腺癌脑转移患者,生存随访至2021年12月31日。
- 共118例患者随机分配,意向治疗队列112例,按2:1随机分配至BEEP诱导3周期后全脑放疗组或单纯全脑放疗组。
- 主要终点为脑特异性无进展生存期(PFS),预设风险比为0.60,双侧α≤0.20,把握度0.8。
主要发现
- 中位年龄56岁(范围34-71岁),61例(54.5%)为ERBB2阳性。
- 中位脑特异性PFS在实验组和对照组分别为8.1个月(范围0.3-29.5)和6.5个月(范围0.9-25.5)(风险比0.71,95%CI 0.44-1.13,P=0.15;在预设α≤0.20下显著)。
- 2个月脑特异性客观缓解率无显著差异(BEEP治疗组41.9% vs 全脑放疗组52.6%)。
- 8个月脑特异性PFS率在实验组显著更高(48.7% vs 26.3%,P=0.03)。
- 不良事件经预防性粒细胞集落刺激因子治疗通常可控。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The incidence of brain metastasis is increasing in patients with metastatic breast cancer. Treatments to extend the control of brain metastasis are urgently required. OBJECTIVE: To investigate whether the addition of an induction treatment of bevacizumab, etoposide, and cisplatin (BEEP) improves brain-specific progression-free survival (PFS) after whole-brain radiotherapy (WBRT). DESIGN, SETTING, AND PARTICIPANTS: This open-label, randomized, multicenter clinical trial assessed patients with brain metastases from breast cancer (BMBC) in Taiwan from September 9, 2014, to December 24, 2018, with survival follow-up until December 31, 2021. Key inclusion criteria included metastatic brain tumors not suitable for focal treatment, WBRT naivety, age 20 to 75 years, and at least 1 measurable brain metastatic lesion. The primary end point was brain-specific PFS, with an expected hazard ratio of 0.60, a 2-sided α ≤ .20, and power of 0.8. INTERVENTIONS: Eligible patients were randomly assigned at a ratio of 2:1 to the experimental arm, which involved 3 cycles of BEEP followed by WBRT, or the control arm, which involved WBRT alone. MAIN OUTCOMES AND MEASURES: The primary end point was the determination of brain-specific PFS by local investigators according to the Response Evaluation Criteria in Solid Tumors, version 1.1, the initiation of other brain-directed treatment after WBRT, or death. Other key end points included brain-specific objective response rate after 8 weeks of BEEP treatment or WBRT and 8-month brain-specific PFS rate, PFS, and overall survival. RESULTS: A total of 118 patients with BMBC were randomized, with the intention-to-treat cohort comprising 112 patients. The median age was 56 years (range, 34-71 years), and 61 patients (54.5%) had ERBB2 (formerly HER2 or HER2/neu)-positive disease. The median (range) brain-specific PFS was 8.1 (0.3-29.5) vs 6.5 (0.9-25.5) months in the experimental and control arms, respectively (hazard ratio, 0.71; 95% CI, 0.44-1.13; P = .15; significant at predefined α ≤ .20). The brain-specific objective response rate at 2 months was not significantly different (BEEP treatment vs WBRT, 41.9% vs 52.6%), but the 8-month brain-specific PFS rate was significantly higher in the experimental group (48.7% vs 26.3%; P = .03). Adverse events were generally manageable with prophylactic granulocyte colony-stimulating factor treatment. CONCLUSIONS AND RELEVANCE: The findings show that induction BEEP before WBRT may improve the control of BMBC compared with using upfront WBRT, which could address an unmet need for an effective systemic treatment for intractable brain and extracranial metastases from metastatic breast cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02185352.
引用
- Chen TW, Dai MS, Tseng LM, et al. Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2024. PMID: 38127335. doi:10.1001/jamaoncol.2023.5456
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。